EC approves first allogeneic T cell therapy for rare post-transplant complication
The European Commission signed off on the continent’s first allogeneic T cell therapy Monday. And for its maker Atara Biotherapeutics, the approval marks the biotech’s first approved therapy.
Ebvallo, made by Atara Biotherapeutics, is now approved by the EMA for marketing authorization for a specific subgroup of patients with post-transplant lymphoproliferative disease who are positive for Epstein-Barr virus. The disease, also known as EBV+ PTLD for short, is a rare complication that can occur after a solid organ or hematopoietic stem cell transplant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
